Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Gately, S; Kerbel, R
   Antiangiogenic scheduling of lower dose cancer chemotherapy
   CANCER JOURNAL
   
   S. Gately e R. Kerbel, "Antiangiogenic scheduling of lower dose cancer chemotherapy", CANCER J, 7(5), 2001, pp. 427-436
2. Atkins, MB; Dutcher, J; Weiss, G; Margolin, K; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J
   Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials
   MEDICAL ONCOLOGY
   
   M.B. Atkins et al., "Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials", MED ONCOL, 18(3), 2001, pp. 197-207
3. Bowers, CY; Granda-Ayala, R
   Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH(2) and in combination in older men and women with decreased growth hormonesecretion
   ENDOCRINE
   
   C.Y. Bowers e R. Granda-Ayala, "Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH(2) and in combination in older men and women with decreased growth hormonesecretion", ENDOCRINE, 14(1), 2001, pp. 79-86
4. Faradji, A; Bonnomet, F; Lecocq, J; Grunebaum, L; Desprez, D; Kern, O; Barbier, L; Sibilia, J
   Knee joint arthroplasty in a patient with haemophilia A and high inhibitortitre using recombinant factor VIIa (NovoSeven((R))): a new case report and review of the literature
   HAEMOPHILIA
   
   A. Faradji et al., "Knee joint arthroplasty in a patient with haemophilia A and high inhibitortitre using recombinant factor VIIa (NovoSeven((R))): a new case report and review of the literature", HAEMOPHILIA, 7(3), 2001, pp. 321-326
5. Chowdary, P; Dasani, H; Jones, JAH; Loran, CM; Eldridge, A; Hughes, S; Collins, PW
   Recombinant factor IX (BeneFix (R)) by adjusted continuous infusion: a study of stability, sterility and clinical experience
   HAEMOPHILIA
   
   P. Chowdary et al., "Recombinant factor IX (BeneFix (R)) by adjusted continuous infusion: a study of stability, sterility and clinical experience", HAEMOPHILIA, 7(2), 2001, pp. 140-145
6. Cid, AR; Lorenzo, JI; Haya, S; Montoro, JM; Casana, P; Aznar, JA
   A comparison of FVII : C and FVIIa assays for the monitoring of recombinant factor VIIa treatment
   HAEMOPHILIA
   
   A.R. Cid et al., "A comparison of FVII : C and FVIIa assays for the monitoring of recombinant factor VIIa treatment", HAEMOPHILIA, 7(1), 2001, pp. 39-41
7. Suresh, S; Anand, KJS
   Opioid tolerance in neonates: a state-of-the-art review
   PAEDIATRIC ANAESTHESIA
   
   S. Suresh e K.J.S. Anand, "Opioid tolerance in neonates: a state-of-the-art review", PAEDIATR AN, 11(5), 2001, pp. 511-521
8. Castagnola, E; Da Ros, L
   Temporary interruption of ceftazidime continuous infusion without reduction of activity: A computer-assisted simulation
   JOURNAL OF CHEMOTHERAPY
   
   E. Castagnola e L. Da Ros, "Temporary interruption of ceftazidime continuous infusion without reduction of activity: A computer-assisted simulation", J CHEMOTHER, 13(4), 2001, pp. 395-401
9. Torres, LM; Rodriguez, MJ; Montero, A; Herrera, J; Calderon, E; Cabrera, J; Porres, R; de la Torre, MR; Martinez, T; Gomez, JL; Ruiz, J; Garcia-Magaz, I; Camara, J; Ortiz, P
   Efficacy and safety of dipyrone versus tramadol in the management of pain after hysterectomy: A randomized, double-blind, multicenter study
   REGIONAL ANESTHESIA AND PAIN MEDICINE
   
   L.M. Torres et al., "Efficacy and safety of dipyrone versus tramadol in the management of pain after hysterectomy: A randomized, double-blind, multicenter study", REG ANES PA, 26(2), 2001, pp. 118-124
10. Tetef, ML; Synold, TW; Chow, W; Leong, L; Margolin, K; Morgan, R; Raschko, J; Shibata, S; Somlo, G; Yen, Y; Groshen, S; Johnson, K; Lenz, HJ; Gandara, D; Doroshow, JH
    Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies
    CLINICAL CANCER RESEARCH
    
    M.L. Tetef et al., "Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies", CLIN CANC R, 7(6), 2001, pp. 1569-1576
11. Grem, JL; Danenberg, KD; Behan, K; Parr, A; Young, L; Danenberg, PV; Nguyen, D; Drake, J; Monks, A; Allegra, CJ
    Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the national cancer institute's anticancer drugscreen
    CLINICAL CANCER RESEARCH
    
    J.L. Grem et al., "Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the national cancer institute's anticancer drugscreen", CLIN CANC R, 7(4), 2001, pp. 999-1009
12. Schindler, J; Sausville, E; Messmann, R; Uhr, JW; Vitetta, ES
    The toxicity of deglycosylated ricin a chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: A retrospective analysis of patients in five clinical trials
    CLINICAL CANCER RESEARCH
    
    J. Schindler et al., "The toxicity of deglycosylated ricin a chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: A retrospective analysis of patients in five clinical trials", CLIN CANC R, 7(2), 2001, pp. 255-258
13. Kirstein, MN; Houghton, PJ; Cheshire, PJ; Richmond, LB; Smith, AK; Hanna, SK; Stewart, CF
    Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts
    CLINICAL CANCER RESEARCH
    
    M.N. Kirstein et al., "Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts", CLIN CANC R, 7(2), 2001, pp. 358-366
14. Nasraway, SA
    Use of sedative medications in the intensive care unit
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
    
    S.A. Nasraway, "Use of sedative medications in the intensive care unit", SEM RESP CR, 22(2), 2001, pp. 165-174
15. Sessler, CN; Grap, MJ; Brophy, GM
    Multidisciplinary management of sedation and analgesia in critical care
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
    
    C.N. Sessler et al., "Multidisciplinary management of sedation and analgesia in critical care", SEM RESP CR, 22(2), 2001, pp. 211-225
16. Poon, MC
    Use of recombinant factor VIIa in hereditary bleeding disorders
    CURRENT OPINION IN HEMATOLOGY
    
    M.C. Poon, "Use of recombinant factor VIIa in hereditary bleeding disorders", CURR OPIN H, 8(5), 2001, pp. 312-318
17. Dillman, RO
    Monoclonal antibody therapy for lymphoma - An update
    CANCER PRACTICE
    
    R.O. Dillman, "Monoclonal antibody therapy for lymphoma - An update", CANCER PRAC, 9(2), 2001, pp. 71-80
18. Pass, SE; Miyagawa, CI; Healy, DP; Ivey, TD
    Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients
    ANNALS OF PHARMACOTHERAPY
    
    S.E. Pass et al., "Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients", ANN PHARMAC, 35(4), 2001, pp. 409-413
19. Witzke, O; Winterhagen, T; Saller, B; Roggenbuck, U; Lehr, I; Philipp, T; Mann, K; Reinhardt, W
    Transient stimulatory effects on pituitary-thyroid axis in patients treated with interleukin-2
    THYROID
    
    O. Witzke et al., "Transient stimulatory effects on pituitary-thyroid axis in patients treated with interleukin-2", THYROID, 11(7), 2001, pp. 665-670
20. Bookman, MA
    Developmental chemotherapy in advanced ovarian cancer: Incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    
    M.A. Bookman, "Developmental chemotherapy in advanced ovarian cancer: Incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group", INT J GYN C, 11, 2001, pp. 42-51
21. Kaufman, HL; DeRaffele, G; Divito, J; Horig, H; Lee, D; Panicali, D; Voulo, M
    A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma
    HUMAN GENE THERAPY
    
    H.L. Kaufman et al., "A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma", HUM GENE TH, 12(11), 2001, pp. 1459-1480
22. Cartron, G; Voillat, L; Desablens, B; Le Maignan, C; Milpied, N; Foussard, C; Dugay, J; Maakaroun, A; De Muret, A; Colombat, P
    Continuous infusion of vincristine-doxorubicin with bolus of Dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma
    LEUKEMIA & LYMPHOMA
    
    G. Cartron et al., "Continuous infusion of vincristine-doxorubicin with bolus of Dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma", LEUK LYMPH, 40(5-6), 2001, pp. 529-540
23. Dillman, RO; DeLeon, C; Beutel, LD; Barth, NM; Schwartzberg, LS; Spitler, LE; Garfield, DH; O'Connor, AA; Nayak, SK
    Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    R.O. Dillman et al., "Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma", CR R ONC H, 39(1-2), 2001, pp. 115-123
24. Launois, R; Portafax, C; Le Lay, K; Megnigbeto, A; Perrocheau, G
    Internet pharmaco-economic studies in metastatic colorectal cancer
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    R. Launois et al., "Internet pharmaco-economic studies in metastatic colorectal cancer", CR R ONC H, 38(1), 2001, pp. 63-77
25. Choy, H
    Taxanes in combined modality therapy for solid tumors
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    H. Choy, "Taxanes in combined modality therapy for solid tumors", CR R ONC H, 37(3), 2001, pp. 237-247
26. Ianniello, GP; Orditura, M; Rossi, A; De Vita, F; Maiorino, L; Carrozza, F; Manzione, L; Catalano, G
    Gemcitabine plus epirubicin in advanced pancreatic cancer: A phase II multicenter trial
    ONCOLOGY REPORTS
    
    G.P. Ianniello et al., "Gemcitabine plus epirubicin in advanced pancreatic cancer: A phase II multicenter trial", ONCOL REP, 8(5), 2001, pp. 1111-1115
27. Berrak, SG; Ewer, MS; Jaffe, N; Pearson, P; Ried, K; Zietz, HA; Benjamin, RS
    Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules
    ONCOLOGY REPORTS
    
    S.G. Berrak et al., "Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules", ONCOL REP, 8(3), 2001, pp. 611-614
28. Bobbio-Pallavicini, E; Tacconi, F; Porta, C; Brambilla, G; Mainardi, E; Bianchessi, C; Moroni, M
    Cisplatin, mitomycin-C, 5-fluorouracil and leucovorin combination chemotherapy (l-FCM) in locally advanced unresectable or metastatic gastric carcinoma: A phase-II study
    ONCOLOGY REPORTS
    
    E. Bobbio-Pallavicini et al., "Cisplatin, mitomycin-C, 5-fluorouracil and leucovorin combination chemotherapy (l-FCM) in locally advanced unresectable or metastatic gastric carcinoma: A phase-II study", ONCOL REP, 8(1), 2001, pp. 167-171
29. Yukimoto, K; Nakata, B; Muguruma, K; Yashiro, M; Ohira, M; Ishikawa, T; Hino, M; Hirakawa, K
    Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastriccancer cells with or without p53 mutation
    INTERNATIONAL JOURNAL OF ONCOLOGY
    
    K. Yukimoto et al., "Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastriccancer cells with or without p53 mutation", INT J ONCOL, 19(2), 2001, pp. 373-378
30. Slifstein, M; Laruelle, M
    Models and methods for derivation of in vivo neuroreceptor parameters withPET and SPECT reversible radiotracers
    NUCLEAR MEDICINE AND BIOLOGY
    
    M. Slifstein e M. Laruelle, "Models and methods for derivation of in vivo neuroreceptor parameters withPET and SPECT reversible radiotracers", NUCL MED BI, 28(5), 2001, pp. 595-608
31. Schmid, P; Possinger, K
    Liposomal anthracyclines for improved cardiac tolerability
    BREAST
    
    P. Schmid e K. Possinger, "Liposomal anthracyclines for improved cardiac tolerability", BREAST, 10, 2001, pp. 22-27
32. D'Antiga, L; Baker, A; Pritchard, J; Pryor, D; Mieli-Vergani, G
    Veno-occlusive disease with multi-organ involvement following actinomycin-D
    EUROPEAN JOURNAL OF CANCER
    
    L. D'Antiga et al., "Veno-occlusive disease with multi-organ involvement following actinomycin-D", EUR J CANC, 37(9), 2001, pp. 1141-1148
33. Maindrault-Goebel, F; de Gramont, A; Louvet, C; Andre, T; Carola, E; Mabro, M; Artru, P; Gilles, V; Lotz, JP; Izrael, V; Krulik, M
    High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
    EUROPEAN JOURNAL OF CANCER
    
    F. Maindrault-Goebel et al., "High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)", EUR J CANC, 37(8), 2001, pp. 1000-1005
34. Comba, AZ; Blajman, C; Richardet, E; Bella, S; Vilanova, M; Coppola, F; Van Kooten, M; Rodger, J; Giglio, R; Balbiani, L; Perazzo, F; Montiel, M; Chacon, M; Pujol, F; Mickiewicz, E; Cazap, E; Recondo, G; Lastiri, F; Simon, J; Wasserman, E; Schmilovich, A
    A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previouslyuntreated metastatic colorectal cancer patients
    EUROPEAN JOURNAL OF CANCER
    
    A.Z. Comba et al., "A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previouslyuntreated metastatic colorectal cancer patients", EUR J CANC, 37(8), 2001, pp. 1006-1013
35. Cunningham, D; James, RD
    Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer
    EUROPEAN JOURNAL OF CANCER
    
    D. Cunningham e R.D. James, "Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer", EUR J CANC, 37(7), 2001, pp. 826-834
36. Smorenburg, CH; Sparreboom, A; Bontenbal, M; Verweij, J
    Combination chemotherapy of the taxanes and antimetabolites: its use and limitations
    EUROPEAN JOURNAL OF CANCER
    
    C.H. Smorenburg et al., "Combination chemotherapy of the taxanes and antimetabolites: its use and limitations", EUR J CANC, 37(18), 2001, pp. 2310-2323
37. Boucard, M; Pinguet, F; Poujol, S; Romieu, G; Cupissol, D; Astre, C; Culine, S; Bressolle, F
    Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer
    EUROPEAN JOURNAL OF CANCER
    
    M. Boucard et al., "Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer", EUR J CANC, 37(18), 2001, pp. 2357-2364
38. Alonso, V; Escudero, P; Zorrilla, M; Isla, MD; Herrero, A; Mayordomo, JI; Martinez-Trufero, J; Saenz, A; Tres, A; Anton, A
    Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer
    EUROPEAN JOURNAL OF CANCER
    
    V. Alonso et al., "Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer", EUR J CANC, 37(18), 2001, pp. 2385-2391
39. Garattini, S; La Vecchia, C
    Perspectives in cancer chemotherapy
    EUROPEAN JOURNAL OF CANCER
    
    S. Garattini e C. La Vecchia, "Perspectives in cancer chemotherapy", EUR J CANC, 37, 2001, pp. S128-S147
40. Jagodic, M; Cufer, T; Zakotnik, B; Cervek, J
    Selection of candidates for oral etoposide salvage chemotherapy in heavilypretreated breast cancer patients
    ANTI-CANCER DRUGS
    
    M. Jagodic et al., "Selection of candidates for oral etoposide salvage chemotherapy in heavilypretreated breast cancer patients", ANTI-CANC D, 12(3), 2001, pp. 199-204
41. Kehrer, DFS; Soepenberg, O; Loos, WJ; Verweij, J; Sparreboom, A
    Modulation of camptothecin analogs in the treatment of cancer: a review
    ANTI-CANCER DRUGS
    
    D.F.S. Kehrer et al., "Modulation of camptothecin analogs in the treatment of cancer: a review", ANTI-CANC D, 12(2), 2001, pp. 89-105
42. Wurthwein, G; Boos, J
    Simulation tool for schedule-dependent etoposide exposure based on pharmacokinetic findings published in the literature
    ANTI-CANCER DRUGS
    
    G. Wurthwein e J. Boos, "Simulation tool for schedule-dependent etoposide exposure based on pharmacokinetic findings published in the literature", ANTI-CANC D, 12(2), 2001, pp. 151-158
43. Jin, FL; Chung, F
    Multimodal analgesia for postoperative pain control
    JOURNAL OF CLINICAL ANESTHESIA
    
    F.L. Jin e F. Chung, "Multimodal analgesia for postoperative pain control", J CLIN ANES, 13(7), 2001, pp. 524-539
44. Le Guen, H; Roy, D; Branger, B; Ecoffey, C
    Comparison of fentanyl and sufentanil in combination with bupivacaine for patient-controlled epidural analgesia during labor
    JOURNAL OF CLINICAL ANESTHESIA
    
    H. Le Guen et al., "Comparison of fentanyl and sufentanil in combination with bupivacaine for patient-controlled epidural analgesia during labor", J CLIN ANES, 13(2), 2001, pp. 98-102
45. Molinari, AC; Castagnola, E; Mazzola, C; Piacentino, M; Fratino, G
    Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters
    SUPPORTIVE CARE IN CANCER
    
    A.C. Molinari et al., "Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters", SUPP CARE C, 9(7), 2001, pp. 539-544
46. Matsota, P; Livanios, S; Marinopoulou, E
    Intercostal nerve block with bupivacaine for post-thoracotomy pain relief in children
    EUROPEAN JOURNAL OF PEDIATRIC SURGERY
    
    P. Matsota et al., "Intercostal nerve block with bupivacaine for post-thoracotomy pain relief in children", EUR J PED S, 11(4), 2001, pp. 219-222
47. Erdlenbruch, B; Pekrun, A; Roth, C; Grunewald, RW; Kern, W; Lakomek, M
    Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions
    PEDIATRIC NEPHROLOGY
    
    B. Erdlenbruch et al., "Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions", PED NEPHROL, 16(7), 2001, pp. 586-593
48. Nicolau, DP; McNabb, J; Lacy, MK; Quintiliani, R; Nightingale, CH
    Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
    
    D.P. Nicolau et al., "Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia", INT J ANT A, 17(6), 2001, pp. 497-504
49. Glimelius, B
    Chemoradiotherapy for rectal cancer - is there an optimal combination?
    ANNALS OF ONCOLOGY
    
    B. Glimelius, "Chemoradiotherapy for rectal cancer - is there an optimal combination?", ANN ONCOL, 12(8), 2001, pp. 1039-1045
50. Rosati, G; Rossi, A; Tucci, A; Pizza, C; Manzione, L
    Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer
    ANNALS OF ONCOLOGY
    
    G. Rosati et al., "Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer", ANN ONCOL, 12(5), 2001, pp. 669-674
51. Louvet, C; Andre, T; Hammel, P; Selle, F; Landi, B; Cattan, S; Fonck, M; Flesch, M; Colin, P; Balosso, J; Ruszniewski, P; de Gramont, A
    Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine foradvanced pancreatic adenocarcinoma (FOLFUGEM)
    ANNALS OF ONCOLOGY
    
    C. Louvet et al., "Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine foradvanced pancreatic adenocarcinoma (FOLFUGEM)", ANN ONCOL, 12(5), 2001, pp. 675-679
52. Saghatchian, M; Fizazi, K; Borel, C; Ducreux, M; Ruffie, P; Le Chevalier, T; Theodore, C
    Carcinoma of an unknown primary site: A chemotherapy strategy based on histological differentiation - results of a prospective study
    ANNALS OF ONCOLOGY
    
    M. Saghatchian et al., "Carcinoma of an unknown primary site: A chemotherapy strategy based on histological differentiation - results of a prospective study", ANN ONCOL, 12(4), 2001, pp. 535-540
53. Bonetti, A; Zaninelli, M; Leone, R; Franceschi, T; Fraccon, AP; Pasini, F; Sabbioni, R; Cetto, GL; Sich, D; Brienza, S; Howell, SB
    Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma
    ANNALS OF ONCOLOGY
    
    A. Bonetti et al., "Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma", ANN ONCOL, 12(2), 2001, pp. 187-191
54. Gallardo, JO; Rubio, B; Fodor, M; Orlandi, L; Yanez, M; Gamargo, C; Ahumada, M
    A phase II study of gemcitabine in gallbladder carcinoma
    ANNALS OF ONCOLOGY
    
    J.O. Gallardo et al., "A phase II study of gemcitabine in gallbladder carcinoma", ANN ONCOL, 12(10), 2001, pp. 1403-1406
55. Nole, F; Munzone, E; Mandala, M; Catania, C; Orlando, L; Zampino, MG; Minchella, I; Colleoni, M; Peruzzotti, G; Marrocco, E; Goldhirsch, A
    Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study
    ANNALS OF ONCOLOGY
    
    F. Nole et al., "Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study", ANN ONCOL, 12(1), 2001, pp. 95-100
56. Shimizu, M; Tamura, T; Yamada, Y; Akiyama, Y; Saijo, N; Nishio, K
    CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNAin mouse liver
    JAPANESE JOURNAL OF CANCER RESEARCH
    
    M. Shimizu et al., "CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNAin mouse liver", JPN J CANC, 92(5), 2001, pp. 554-561
57. Coleman, M; Leonard, J; Shuster, MW; Kaufman, TP
    DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL)
    EUROPEAN JOURNAL OF HAEMATOLOGY
    
    M. Coleman et al., "DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL)", EUR J HAEMA, 66, 2001, pp. 41-45
58. Jokinen, MJ; Ahonen, J; Neuvonen, PJ; Olkkola, KT
    Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine
    PHARMACOLOGY & TOXICOLOGY
    
    M.J. Jokinen et al., "Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine", PHARM TOX, 88(4), 2001, pp. 187-191
59. Khayat, D; Gil-Delgado, M; Antoine, EC; Nizri, D; Bastian, G
    The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer
    ONCOLOGY-NEW YORK
    
    D. Khayat et al., "The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer", ONCOLOGY-NY, 15(4), 2001, pp. 415-429
60. Sun, WJ; Haller, DG
    The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer - The Khayat et al article reviewed
    ONCOLOGY-NEW YORK
    
    W.J. Sun e D.G. Haller, "The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer - The Khayat et al article reviewed", ONCOLOGY-NY, 15(4), 2001, pp. 430
61. Haller, DG
    Update on chemotherapy for advanced colorectal cancer
    ONCOLOGY-NEW YORK
    
    D.G. Haller, "Update on chemotherapy for advanced colorectal cancer", ONCOLOGY-NY, 15(3), 2001, pp. 11-15
62. Berlin, JD; Rothenberg, M
    Chemotherapy for resectable and advanced pancreatic cancer
    ONCOLOGY-NEW YORK
    
    J.D. Berlin e M. Rothenberg, "Chemotherapy for resectable and advanced pancreatic cancer", ONCOLOGY-NY, 15(10), 2001, pp. 1241
63. Ahlgren, JD
    Chemotherapy for resectable and advanced pancreatic cancer - The Berlin/Rothenberg article reviewed
    ONCOLOGY-NEW YORK
    
    J.D. Ahlgren, "Chemotherapy for resectable and advanced pancreatic cancer - The Berlin/Rothenberg article reviewed", ONCOLOGY-NY, 15(10), 2001, pp. 1254-1256
64. Bernstein, ML; Reaman, GH; Hirschfeld, S
    Developmental therapeutics in childhood cancer - A perspective from the Children's Oncology Group and the US Food and Drug Administration
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    
    M.L. Bernstein et al., "Developmental therapeutics in childhood cancer - A perspective from the Children's Oncology Group and the US Food and Drug Administration", HEMAT ONCOL, 15(4), 2001, pp. 631
65. Hunault-Berger, M; Milpied, N; Bernard, M; Jouet, JP; Delain, M; Desablens, B; Sadoun, A; Guilhot, F; Casassus, P; Ifrah, N
    Daunorubicin continuous infusion induces more toxicity than bolus infusionin acute lymphoblastic leukemia induction regimen: a randomized study
    LEUKEMIA
    
    M. Hunault-Berger et al., "Daunorubicin continuous infusion induces more toxicity than bolus infusionin acute lymphoblastic leukemia induction regimen: a randomized study", LEUKEMIA, 15(6), 2001, pp. 898-902
66. Ahlmann, M; Lanvers, C; Lumkemann, K; Rossig, C; Freund, A; Baumann, M; Boos, J
    Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells
    LEUKEMIA
    
    M. Ahlmann et al., "Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells", LEUKEMIA, 15(1), 2001, pp. 69-73
67. Pereira, J; Lawlor, P; Vigano, A; Dorgan, M; Bruera, E
    Equianalgesic dose ratios for opioids: A critical review and proposals forlong-term dosing
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
    
    J. Pereira et al., "Equianalgesic dose ratios for opioids: A critical review and proposals forlong-term dosing", J PAIN SYMP, 22(2), 2001, pp. 672-687
68. Zhou, H; Shen, V; Dempster, DW; Lindsay, R
    Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat
    JOURNAL OF BONE AND MINERAL RESEARCH
    
    H. Zhou et al., "Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat", J BONE MIN, 16(7), 2001, pp. 1300-1307
69. Chelly, JE; Greger, J; Gebhard, R; Coupe, K; Clyburn, TA; Buckle, R; Criswell, A
    Continuous femoral blocks improve recovery and outcome of patients undergoing total knee arthroplasty
    JOURNAL OF ARTHROPLASTY
    
    J.E. Chelly et al., "Continuous femoral blocks improve recovery and outcome of patients undergoing total knee arthroplasty", J ARTHROPLA, 16(4), 2001, pp. 436-445
70. Green, SM; Denmark, TK; Cline, J; Roghair, C; Abd Allah, S; Rothrock, SG
    Ketamine sedation for pediatric critical care procedures
    PEDIATRIC EMERGENCY CARE
    
    S.M. Green et al., "Ketamine sedation for pediatric critical care procedures", PEDIAT EMER, 17(4), 2001, pp. 244-248
71. Szokol, JW; Vender, JS
    Anxiety, delirium, and pain in the intensive care unit
    CRITICAL CARE CLINICS
    
    J.W. Szokol e J.S. Vender, "Anxiety, delirium, and pain in the intensive care unit", CRIT CARE C, 17(4), 2001, pp. 821
72. Young, CC; Prielipp, RC
    Benzodiazepines in tide intensive care unit
    CRITICAL CARE CLINICS
    
    C.C. Young e R.C. Prielipp, "Benzodiazepines in tide intensive care unit", CRIT CARE C, 17(4), 2001, pp. 843
73. Ibrahim, NK; Valero, V; Rahman, Z; Theriault, RL; Walters, RS; Buzdar, AU; Booser, DJ; Holmes, FA; Murray, DJ; Willey, J; Bast, R; Hortobagyi, GN
    Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation
    CANCER INVESTIGATION
    
    N.K. Ibrahim et al., "Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation", CANCER INV, 19(5), 2001, pp. 459-466
74. Freyer, G; Bossard, N; Romestaing, P; Mornex, F; Chapet, O; Trillet-Lenoir, V; Gerard, JP
    Addition of oxaliplatin to continuous fluorouracil, L-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 Phase I trial
    JOURNAL OF CLINICAL ONCOLOGY
    
    G. Freyer et al., "Addition of oxaliplatin to continuous fluorouracil, L-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 Phase I trial", J CL ONCOL, 19(9), 2001, pp. 2433-2438
75. Hoff, PM; Ansari, R; Batist, G; Cox, J; Kocha, W; Kuperminc, M; Maroun, J; Walde, D; Weaver, C; Harrison, E; Burger, HU; Osterwalder, B; Wang, AO; Wong, R
    Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
    JOURNAL OF CLINICAL ONCOLOGY
    
    P.M. Hoff et al., "Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study", J CL ONCOL, 19(8), 2001, pp. 2282-2292
76. Dorr, R; Karanes, C; Spier, C; Grogan, T; Greer, J; Moore, J; Weinberger, B; Schiller, G; Pearce, T; Litchman, M; Dalton, W; Roe, D; List, AF
    Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia
    JOURNAL OF CLINICAL ONCOLOGY
    
    R. Dorr et al., "Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia", J CL ONCOL, 19(6), 2001, pp. 1589-1599
77. Becouarn, Y; Gamelin, E; Coudert, B; Negrier, S; Pierga, JY; Raoul, JL; Provencal, J; Rixe, O; Krisch, C; Germa, C; Bekradda, M; Mignard, D; Mousseau, M
    Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients
    JOURNAL OF CLINICAL ONCOLOGY
    
    Y. Becouarn et al., "Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients", J CL ONCOL, 19(22), 2001, pp. 4195-4201
78. Van Cutsem, E; Twelves, C; Cassidy, J; Allman, D; Bajetta, E; Boyer, M; Bugat, R; Findlay, M; Frings, S; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Vieitez, JM; Weitzel, C; Harper, P
    Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
    JOURNAL OF CLINICAL ONCOLOGY
    
    E. Van Cutsem et al., "Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study", J CL ONCOL, 19(21), 2001, pp. 4097-4106
79. Falcone, A; Di Paolo, A; Masi, G; Allegrini, G; Danesi, R; Lencioni, M; Pfanner, E; Comis, S; Del Tacca, M; Conte, P
    Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients
    JOURNAL OF CLINICAL ONCOLOGY
    
    A. Falcone et al., "Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients", J CL ONCOL, 19(15), 2001, pp. 3456-3462
80. Saylors, RL; Stine, KC; Sullivan, J; Kepner, JL; Wall, DA; Bernstein, ML; Harris, MB; Hayashi, R; Vietti, TJ
    Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study
    JOURNAL OF CLINICAL ONCOLOGY
    
    R.L. Saylors et al., "Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study", J CL ONCOL, 19(15), 2001, pp. 3463-3469
81. Heinzer, H; Huland, E; Huland, H
    Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer
    WORLD JOURNAL OF UROLOGY
    
    H. Heinzer et al., "Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer", WORLD J URO, 19(2), 2001, pp. 111-119
82. Nolte, W; Ramadori, G
    New aspects in the palliative treatment of metastatic colorectal carcinoma
    MEDIZINISCHE KLINIK
    
    W. Nolte e G. Ramadori, "New aspects in the palliative treatment of metastatic colorectal carcinoma", MED KLIN, 96(9), 2001, pp. 521-528
83. Locher, C; Auperin, A; Boige, V; Alzieu, L; Pignon, JP; Abbas, M; Ducreux, M
    Assessment of the cost of first line chemotherapy in metastatic colorectalcancer. Preliminary results in the FFCD 9601 trial
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
    
    C. Locher et al., "Assessment of the cost of first line chemotherapy in metastatic colorectalcancer. Preliminary results in the FFCD 9601 trial", GASTRO CL B, 25(8-9), 2001, pp. 749-754
84. Louvet, C
    New chemotherapies for colorectal cancer treatment
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE
    
    C. Louvet, "New chemotherapies for colorectal cancer treatment", GASTRO CL B, 25(4), 2001, pp. B51-B56
85. Mimoz, O
    Antibiotic administration in Gram-negative bacilli infections.
    MEDECINE ET MALADIES INFECTIEUSES
    
    O. Mimoz, "Antibiotic administration in Gram-negative bacilli infections.", MED MAL INF, 31(10), 2001, pp. 583-590
86. Oberhoff, C; Kieback, DG; Wurstlein, R; Deertz, H; Sehouli, J; van Soest, C; Hilfrich, J; Mesrogli, M; von Minckwitz, G; Staab, HJ; Schindler, AE
    Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study
    ONKOLOGIE
    
    C. Oberhoff et al., "Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study", ONKOLOGIE, 24(3), 2001, pp. 256-260
87. Honecker, F; Wedding, U; Kolb, G; Bokemeyer, C
    Chemotherapy in colorectal cancer - Which therapy is justified in elderly patients?
    ONKOLOGIE
    
    F. Honecker et al., "Chemotherapy in colorectal cancer - Which therapy is justified in elderly patients?", ONKOLOGIE, 24(1), 2001, pp. 87-94
88. Hartung, G
    New developments in chemotherapy of gastrointestinal carcinomas
    ONKOLOGIE
    
    G. Hartung, "New developments in chemotherapy of gastrointestinal carcinomas", ONKOLOGIE, 24, 2001, pp. 10-15
89. Compton, P; Charuvastra, VC; Ling, W
    Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent
    DRUG AND ALCOHOL DEPENDENCE
    
    P. Compton et al., "Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent", DRUG AL DEP, 63(2), 2001, pp. 139-146
90. Wiig, H; Tenstad, O
    Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
    
    H. Wiig e O. Tenstad, "Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle", AM J P-HEAR, 280(4), 2001, pp. H1505-H1512
91. Sanfilippo, NJ; Crane, CH; Skibber, J; Feig, B; Abbruzzese, JL; Curley, S; Vauthey, JN; Ellis, LM; Hoff, P; Wolff, RA; Brown, TD; Cleary, K; Wong, A; Phan, T; Janjan, NA
    T4 rectal cancer treated with preoperative chemoradiation to the posteriorpelvis followed by multivisceral resection: Patterns of failure and limitations of treatment
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    
    N.J. Sanfilippo et al., "T4 rectal cancer treated with preoperative chemoradiation to the posteriorpelvis followed by multivisceral resection: Patterns of failure and limitations of treatment", INT J RAD O, 51(1), 2001, pp. 176-183
92. Fu, CH; Martin-Aragon, S; Weinberg, KI; Ardi, VC; Danenberg, PV; Avramis, VI
    Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    C.H. Fu et al., "Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein", CANC CHEMOT, 48(2), 2001, pp. 123-133
93. Morgan, RJ; Synold, T; Carr, BI; Doroshow, JH; Womack, EP; Shibata, S; Somlo, G; Raschko, J; Leong, L; McNamara, M; Chow, W; Tetef, M; Margolin, K; Akman, S; Longmate, J
    Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    R.J. Morgan et al., "Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy", CANC CHEMOT, 47(4), 2001, pp. 327-332
94. Yule, SM; Price, L; Cole, M; Pearson, ADJ; Boddy, AV
    Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    S.M. Yule et al., "Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion", CANC CHEMOT, 47(3), 2001, pp. 222-228
95. Dowlati, A; Levitan, N; Gordon, NH; Hoppel, CL; Gosky, DM; Remick, SC; Ingalls, ST; Berger, SJ; Berger, NA
    Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    A. Dowlati et al., "Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer", CANC CHEMOT, 47(2), 2001, pp. 141-148
96. Herrington, JD; Figueroa, JA; Kirstein, MN; Zamboni, WC; Stewart, CF
    Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    J.D. Herrington et al., "Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction", CANC CHEMOT, 47(1), 2001, pp. 89-93
97. van der Vorst, MMJ; van Heel, IRD; Kist-van Holthe, JE; den Hartigh, J; Schoemaker, RC; Cohen, AF; Burggraaf, J
    Continuous intravenous furosemide in haemodynamically unstable children after cardiac surgery
    INTENSIVE CARE MEDICINE
    
    M.M.J. van der Vorst et al., "Continuous intravenous furosemide in haemodynamically unstable children after cardiac surgery", INTEN CAR M, 27(4), 2001, pp. 711-715
98. Smith, MP; Ludlam, CA; Collins, PW; Hay, CRM; Wilde, JT; Grigeri, A; Melsen, T; Savidge, GF
    Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII - Plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding
    THROMBOSIS AND HAEMOSTASIS
    
    M.P. Smith et al., "Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII - Plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding", THROMB HAEM, 86(4), 2001, pp. 949-953
99. Santagostino, E; Morfini, M; Rocino, A; Baudo, F; Scaraggi, FA; Gringeri, A
    Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors
    THROMBOSIS AND HAEMOSTASIS
    
    E. Santagostino et al., "Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors", THROMB HAEM, 86(4), 2001, pp. 954-958
100. Kerbusch, T; de Kraker, J; Mathot, RAA; Beijnen, JH
     Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease - A sparse sampling approach
     CLINICAL PHARMACOKINETICS
     
     T. Kerbusch et al., "Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease - A sparse sampling approach", CLIN PHARMA, 40(8), 2001, pp. 615-625